COVID-19 Vaccine: A comprehensive status report
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ahn, 2020, Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea, J Korean Med Sci, 35, 10.3346/jkms.2020.35.e149
Ahn, 2020, Use of convalescent plasma therapy in two covid‐19 patients with acute respiratory distress syndrome in Korea, J Korean Med Sci., 10.3346/jkms.2020.35.e149
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
Anon, 2020
2020
Anon, 2020
Anon, 2020, Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Chest
Anon, 2020
Arora, 2020, Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate. Gurugram : s.n, bioRxiv
Baruah, 2020, Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV, J Med Virol., 495, 10.1002/jmv.25698
BROOK, STONY, 2020
Campbell, 2020
Cao, 2018, Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant, Nat Commun., 10.1038/s41467-018-06151-y
Carter, 2007, 382
(CDC), Centers for Disease Control and Prevention, 2020
CDC, 2020, Coronavirus Disease 2019 (COVID-19)- Symptoms of Covid-19, Centres for Disease Control and Prevention
Coleman, 2020, Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice, Vaccine, 3169
Conserved Protein Domain Family: SARS-like-CoV_M, 2020
Coronavirus, 2020
CTRI/2020/07/026352. 2020 http://ctri.nic.in/. [Online] July 31, 2020. [Cited: August 01, 2020.] http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&EncHid=&userName=Zydus.
Cuiling, 2020, Advances in mRNA Vaccines for Infectious Diseases, Frontiers in Immunology, 594
da Silva, 2020, Role of Nonstructural Proteins in the Pathogenesis of SARS-CoV-2, Journal of medical virology, 10.1002/jmv.25858
Delamater, 2019, Complexity of the Basic Reproduction Number (R0), s.l. : Emerging Infectious Diseases, 25
Dhama, 2020, COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics, Hum Vaccin Immunother, 10.1080/21645515.2020.1735227
Doremalen, 2020, Jonathan ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques, s.l. : bioRxiv
Dorp, 2020, Emergence of genomic diversity and recurrent mutations in SARS-CoV-2, s.l. : Infection, Genetics and Evolution, 104351
Eyal, 2020, Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure, s.l. : The Journal of infectious diseases, 1752
Folegatti, 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, The Lancet
Garg, 2020, An Integrated In-Silico Approach to Develop Epitope-Based Peptide Vaccine against SARS-CoV-2, s.l. : Preprints
Gelboin, 1999, Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery, Trends in Pharmacological Sciences., 432, 10.1016/S0165-6147(99)01382-6
Gupta, 2006, SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens, Virology, 347, 127, 10.1016/j.virol.2005.11.042
Heat Biologics’ COVID-19 Vaccine Program, 2020
Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 271, 10.1016/j.cell.2020.02.052
Imai, 2020, Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development, Proceedings of the National Academy of Sciences, 16587, 10.1073/pnas.2009799117
Jackson, 2020, An mRNA Vaccine against SARS-CoV-2 — Preliminary Report, N Engl J Med.
Jiang, 2020, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies, Emerging microbes & infections, 275, 10.1080/22221751.2020.1723441
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19, 2020
Kai, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proceedings of the National Academy of Sciences
Kim, 2020, Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development, EBioMedicine, 10.1016/j.ebiom.2020.102743
Lauer, 2020, The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application, Ann Intern Med., 577, 10.7326/M20-0504
Le, 2020, The COVID-19 vaccine development landscape, Nature Reviews Drug Discovery, 19, 305, 10.1038/d41573-020-00073-5
Lee, 2020, These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand, Market watch
Liu, 2020, Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases, ACS Central Science, 315, 10.1021/acscentsci.0c00272
Masihi, 2001, Fighting infection using immunomodulatory agents, Expert Opinion on Biological Therapy, 641, 10.1517/14712598.1.4.641
Mice, 2020, The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic, s.l. : bioRxiv
Michot, 2020, Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Annals of Oncology, 10.1016/j.annonc.2020.03.300
Mulligan, 2020, Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report; preprint, s.l. : medRxiv
Myupchar, 2020
Nandi, 2020
Ning, 2020, Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses, Frontiers in Microbiology
Novavax covid 19 vaccine trial, 2020
Ou, 2020, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat Commun, 1620, 11
Park, 2020, Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19), Clin Exp Pediatr, 119, 10.3345/cep.2020.00493
Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs, 2020
PIB, Delhi, 2020
Prof Roujian, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, The Lancet, 565
Pyrek, 2018
Shang, 2020, The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines, NPJ Vaccines, 10.1038/s41541-020-0170-0
Shen, 2020, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783
Shen, 2020, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, JAMA, 323, 1582, 10.1001/jama.2020.4783
Smith, 2020, Immunogenicity of a DNA vaccine candidate for COVID-19. 2601, s.l. : Nat Commun, 11
Tai, 2020, Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cell Mol Immunol, 10.1038/s41423-020-0400-4
TNX-1800 (Coronavirus Vaccine), 2020
Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific, Emerg Microbes Infect, 382, 10.1080/22221751.2020.1729069
Tu, 2020, A Review of SARS-CoV-2 and the Ongoing Clinical Trials, International Journal of Molecular Sciences, 2657, 10.3390/ijms21072657
Upadhyay, 2020
Ura, 2014, Developments in Viral Vector-Based Vaccines, Vaccines (Basel), 624, 10.3390/vaccines2030624
Voltron Therapeutics, Inc, 2020
Walls, 2020, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 281, 10.1016/j.cell.2020.02.058
Walls, 2020, Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein, Cell, 281, 10.1016/j.cell.2020.02.058
Wan, 2020, Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS, J Virol., 10.1128/JVI.00127-20
(WHO), World Health Organisation, 2014
(WHO) World Health Organisation, 2020
WHO, 2020
Wrapp, 2020, Mclellan Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 1260, 10.1126/science.abb2507
Wu, 2020, Commentary genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China, Cell Host Microbe, 325, 10.1016/j.chom.2020.02.001
Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med., 10.1016/S2213-2600(20)30076-X
Yan, Xuebing. 2020 http://www.chictr.org.cn/showprojen.aspx?proj=49544. http://www.chictr.org.cn. [Online] February 2020.
Yip, 2016, Hong Kong Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS: s.n, Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine, 25
Yoshimoto, 2020, The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19, The protein journal, 198, 10.1007/s10930-020-09901-4
Zhai, 2020, The epidemiology, diagnosis and treatment of COVID-19, International Journal of Antimicrobial Agents, 10.1016/j.ijantimicag.2020.105955
Zhang, 2020, Treatment with convalescent plasma for critically ill patients with SARS‐CoV‐2 infection, Chest, 2020, 30571
Zhu, 2020, Safety, tolerability, and immunogenicity of a recombinan tadenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, The Lancet
Zhu, 2020, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet